Circulating Deoxyribonucleic Acid As Prognostic Marker in Non–Small-Cell Lung Cancer Patients Undergoing Chemotherapy

Gautschi, Oliver; Bigosch, Colette; Huegli, B.; Jermann, Monika; Marx, Arthur; Chassé, Eveline; Ratschiller, Daniel; Weder, Walter; Joerger, Markus; Betticher, Daniel; Stahel, Rolf A.; Ziegler, Annemarie

doi:10.1200/jco.2004.11.123

Cited by 246 publications

(263 citation statements)

References 20 publications

Supporting

Mentioning

228

Contrasting

Unclassified

Order By: Relevance

“…Although the precise mechanism of DNA release into the blood remains uncertain, it probably derives from a combination of apoptosis, necrosis and active release from tumour cells [6]. Such cell-free DNA has shown promise for improving early clinical diagnosis, prognostication and disease monitoring in inaccessible tumour types, such as lung cancer [7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Optimizing the yield and utility of circulating cell-free DNA from plasma and serum

Xue

Teare

Holen

et al. 2009

Clinica Chimica Acta

142

114

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Optimizing the yield and utility of circulating cell-free DNA from plasma and serum

Xue

Teare

Holen

et al. 2009

Clinica Chimica Acta

142

114

View full text Add to dashboard Cite

show abstract

“…To date, many candidate markers have been reported in relation to the clinical outcome of HCC patients (Marrero and Lok, 2004;Kuramitsu and Nakamura, 2006). In addition to these biomarkers, circulating cell-free DNA (cfDNA) has attracted a great deal of attention as an easy-to-use tool for evaluation of the malignant potential of cancer (Gautschi et al, 2004;Umetani et al, 2006). By means of real-time polymerase chain reaction (PCR) assay, we found that cfDNA levels were significantly higher in sera from patients with HCV-related HCC than in sera from HCV carriers without known HCC (Iizuka et al, 2006a).…”

mentioning

confidence: 99%

Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma

et al. 2007

View full text Add to dashboard Cite

In a previous study, we showed that levels of cell-free DNA (cfDNA) were significantly higher in sera of patients with hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV) than in sera of non-HCC patients with HCV. To confirm this finding, we analysed serum cfDNA levels in a cohort of 96 patients with HCV-related HCC and in 100 HCV carriers without known HCC. Again we found that serum cfDNA levels were significantly higher in HCC patients than in HCV carriers (115.9 ± 98.3 vs 34.4 ± 40.4 ng ml À1 (mean ± s.d.), Po0.0001). Of 87 eligible patients who underwent curative hepatectomy, those with a high cfDNA level had a significantly shorter overall survival (OS) time than those in whom the cfDNA level was not high. Cox proportional hazards model showed the cfDNA level to be an independent prognostic factor for OS and cancer recurrence in distant organs. Our results suggest that the serum cfDNA level reflects the metastatic potential of HCV-related HCC and that it can be a useful predictive biomarker for distant metastasis after curative surgery.

show abstract

“…Qualitative alterations in circulating DNA, such as microsatellite alterations [10], oncogene mutations [11], mitochondrial DNA, tumour-speciWc methylated DNA [12] and viral DNA [13], have been found in patients with diVerent types of cancer. Quantitative alterations of circulating cfDNA have also been observed in several cancers, such as prostate cancer [14], lung cancer [15], pancreatic cancer [16], leukaemia and lymphoma [17]. High levels of circulating cfDNA were correlated with tumour metastasis, response to therapy and recurrence [15,18].…”

Section: Introductionmentioning

confidence: 99%

“…Quantitative alterations of circulating cfDNA have also been observed in several cancers, such as prostate cancer [14], lung cancer [15], pancreatic cancer [16], leukaemia and lymphoma [17]. High levels of circulating cfDNA were correlated with tumour metastasis, response to therapy and recurrence [15,18].…”

Section: Introductionmentioning

confidence: 99%

Elevated level of cell-free plasma DNA is associated with breast cancer

Zhong

Ladewig

Schmid

et al. 2007

Arch Gynecol Obstet

View full text Add to dashboard Cite

Background We analysed cell-free DNA (cfDNA) in the plasma of patients with both malignant and benign breast lesions by real-time quantitative PCR to determine whether the Wnding may have diagnostic and prognostic implications. Methods Plasma samples were obtained from 33 patients with breast cancer, 32 patients with benign breast lesions and 50 healthy women as normal controls. Circulatory cfDNA was extracted from the plasma samples and quantiWed by real-time quantitative PCR for the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene. Results The mean concentrations of cfDNA in the plasma samples from patients with breast cancer, patients with benign breast lesions and normal controls were 2,285, 1,368 and 1,489 genome equivalents (GE) per millilitre, respectively. The level of cfDNA in the breast cancer group was signiWcantly higher than those in the benign lesion group and control group (P = 0.007 and 0.013, respectively). These Wndings were associated with malignant tumour size. The levels of the cfDNA were high in patients with lymph node involvement and distant metastasis. Conclusions Our results suggest that levels of cfDNA in the plasma are elevated in malignant breast cancer and correlated with tumour size. These Wndings could have diagnostic and prognostic value for malignant breast tumours.

show abstract

Circulating Deoxyribonucleic Acid As Prognostic Marker in Non–Small-Cell Lung Cancer Patients Undergoing Chemotherapy

Abstract: Our data demonstrate that quantification of plasma DNA is an accurate technique amenable to standardization, which might complement current methods for the prediction of patient survival. This approach might be considered for evaluation in large prospective studies.

Cited by 246 publications

References 20 publications

Optimizing the yield and utility of circulating cell-free DNA from plasma and serum

Optimizing the yield and utility of circulating cell-free DNA from plasma and serum

Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma

Elevated level of cell-free plasma DNA is associated with breast cancer

Contact Info

Product

Resources

About